Northwire Canada EditionThursday, July 16, 2026
Sign inSubscribe
Northwire
⌕
SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.45 +0.0% CAM 0.330 −1.5% SYH 0.400 −1.2% LOT 0.040 +0.0% SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.45 +0.0% CAM 0.330 −1.5% SYH 0.400 −1.2% LOT 0.040 +0.0%

Healthcare

Page 89
  1. Dec 09, 2025 · 10:31 · SPLY

    Safe Supply Announces Upsize to Non-Brokered Private Placement

    Safe Supply Announces Upsize to Non-Brokered Private Placement

    01
  2. Dec 09, 2025 · 10:28 · BNXT

    Bionxt working on melt-in-your-mouth cladribine product

    Bionxt working on melt-in-your-mouth cladribine product

    02
  3. Dec 09, 2025 · 09:01 · OTC

    Ocumetics Announces Optimized Lens Delivery System in Collaboration with Medicel

    Ocumetics Announces Optimized Lens Delivery System in Collaboration with Medicel

    03
  4. Dec 09, 2025 · 07:30 · BCT

    BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

    BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

    04
  5. Dec 09, 2025 · 07:00 · FRX

    Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors

    Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors

    05
  6. Dec 09, 2025 · 07:00 · MSCL

    Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy

    Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy

    06
  7. Dec 09, 2025 · 03:05 · BNXT

    BioNxt Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia

    BioNxt Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia

    07
  8. Dec 08, 2025 · 19:23 · BHC

    Bausch Health Announces Early Exchange Offer Results for Exchange Offers

    Bausch Health Announces Early Exchange Offer Results for Exchange Offers

    08
  9. Dec 08, 2025 · 19:02 · AIDR

    Rocket Doctor AI, CAN Health Network enter partnership

    Rocket Doctor AI, CAN Health Network enter partnership

    09
  10. Dec 08, 2025 · 18:24 · IZO

    Izotropic to issue 240,000 units for note interest

    Izotropic to issue 240,000 units for note interest

    10
  11. Dec 08, 2025 · 17:01 · VIVI

    TempraMed Announces Strategic Agreement with Maccabi Healthcare Services, a Leading HMO with over 2.8 Million Patients

    TempraMed Announces Strategic Agreement with Maccabi Healthcare Services, a Leading HMO with over 2.8 Million Patients

    11
  12. Dec 08, 2025 · 16:14 · WELL

    Well Health's Wellstar closes $62-million financing

    Well Health's Wellstar closes $62-million financing

    12
  13. Dec 08, 2025 · 13:17 · VPT

    From Hype to P&L: Hospitals Now Buying AI That Pays

    From Hype to P&L: Hospitals Now Buying AI That Pays

    13
  14. Dec 08, 2025 · 10:30 · 4151

    Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI(TM) (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML

    Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI(TM) (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML

    14
← Newer Older →